Effects of green tea consumption on fatigue, depression and anxiety scores in COVID-19 patients

INTERVENTION: Intervention 1: Intervention group: Patients with Covid 19 will be consumed daily with three cups of green tea equivalent to 12 grams of green tea per day from Heshmat Fooman tea factory for four weeks. Intervention 2: Control group: Patients with Covid 19 will be consumed daily with three cups of black tea equivalent to 12 grams of black tea per day from Heshmat Fooman tea factory for four weeks. CONDITION: Coronavirus disease. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: C‐reactive protein. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device. Complete blood cell count and diffrential count. Timepoint: At the beginning of the study and one month later. Method of measurement: Cell counter devices. Creatinine phosphokinase. Timepoint: At the beginning of the study and one month later. Method of measurement: Biochemical autoanalyzer. D‐dimer. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device. Ferritin. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device. Lactate dehydrogenase. Timepoint: At the beginning of the study and one month later. Method of measurement: Biochemical autoanalyzer. Severity of the viral infection clinical symptoms. Timepoint: At the beginning of the study and 7, 14 and 21 days after tea consumption. Method of measurement: The severity of clinical signs of viral infection will be detected through a respiratory rate more than 24 or a heart rate greater than 125 or the patient requires mechanical ventilation or saturation of peripheral oxygen less than 94% and also based on the patient's laboratory results including D‐ dimer more than 1000; creatinine phosphokinase twice the normal amount; positive troponin; progressive lymphopenia; ferritin more than 300. Troponin. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device. SECONDARY OUTCOME: Depression score based on Patients Health Questionnaire‐9. Timepoint: At the beginning of the study and one month later. Method of measurement: Patients Health Questionnaire‐9. Scale of anxiety based on State‐Trait Anxiety Inventory (STAI) Questionnaire. Timepoint: At the beginning of the study and one month later. Method of measurement: State‐Trait Anxiety Inventory (STAI) Questionnaire. Scale of fatigue based on Chalder Fatigue Scale (CFQ‐11). Timepoint: At the beginning of the study and one month later. Method of measurement: Chalder Fatigue Scale (CFQ‐11) Questionnaire. INCLUSION CRITERIA: patients with COVID‐19 Twice positive PCR test Age over 20 years Provide written consent to enter the study Not participating in other clinical trials no use of other types of herbal teas